Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
These findings follow positive Phase 3 results presented earlier this year
Merck will showcase results in innovative solutions in HIV treatment and prevention
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Marks first international filing for Evofem’s single-dose oral treatment
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Subscribe To Our Newsletter & Stay Updated
